Elicera Therapeutics Management

Management Kriterienprüfungen 2/4

Elicera Therapeutics CEO ist Jamal El-Mosleh , ernannt in Jan 2020, hat eine Amtszeit von 4.83 Jahren. besitzt direkt 8.39% der Aktien des Unternehmens, im Wert von SEK5.02M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.3 Jahre bzw. 4.8 Jahre.

Wichtige Informationen

Jamal El-Mosleh

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	4.8yrs
Eigentum des Geschäftsführers	8.4%
Durchschnittliche Amtszeit des Managements	4.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.8yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Jamal El-Mosleh (43 yo)

4.8yrs

Amtszeit

Mr. Jamal El-Mosleh, M.Sc., is Co-Founder at Elicera Therapeutics AB (publ) and has been its CEO since 2020. He was a Director of Elypta AB since 2016 until September 2020. Mr. El-Mosleh served as Chief Ex...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jamal El-Mosleh	CEO & Co-Founder	4.8yrs	keine Daten	8.39% SEK 5.0m
Magnus Essand	Chief Science Officer	4.8yrs	keine Daten	9.6% SEK 5.7m
Di Yu	Co-Founder & Head of Transitional Research	no data	keine Daten	9.76% SEK 5.8m
Ingvar Karlsson	Chief Financial Officer	3.8yrs	keine Daten	0.10% SEK 61.4k
Anna Gultekin	Head of Regulatory Affairs	1.8yrs	keine Daten	keine Daten

4.3yrs

Durchschnittliche Betriebszugehörigkeit

51.5yo

Durchschnittliches Alter

Erfahrenes Management: ELICDas Führungsteam des Unternehmens gilt als erfahren (4.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Magnus Essand	Chief Science Officer	10.8yrs	keine Daten	9.6% SEK 5.7m
Margareth Jorvid	Independent Director	4.8yrs	keine Daten	0.20% SEK 117.0k
Agneta Edberg	Independent Chairman	4.8yrs	keine Daten	0.34% SEK 205.1k
Christina Herder	Independent Director	4.8yrs	keine Daten	0.16% SEK 96.3k
Sharon Longhurst	Independent Director	less than a year	keine Daten	keine Daten

4.8yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: ELICDie Vorstandsmitglieder gelten als erfahren (4.8 Jahre durchschnittliche Amtszeit).

Elicera Therapeutics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024

Elicera Therapeutics AB (Publ) Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Elicera Therapeutics Includes the First Patient in the Phase I/II Clinical Study Carma Targeting B-Cell Lymphoma

Elicera Therapeutics AB (publ) Enrolls the Last Patient in the Clinical Phase I/II-Trial with Oncolytic Virus ELC-100

New major risk - Financial position

Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA

New major risk - Shareholder dilution

Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024

New major risk - Financial position

Elicera Therapeutics AB (publ) to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1

Elicera Therapeutics AB (Publ) Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301

Elicera Therapeutics Receives Approval to Initiate Clinical Phase I/II-Study Carma with Car T-Cell Therapy ELC-301 in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research

Elicera Therapeutics AB (publ) Submits GMP Validation Data to the Swedish Medical Products Agency for the CARMA Study to Supplement the Conditionally Approved Clinical Trial Application

New major risk - Share price stability

Elicera Therapeutics AB (Publ) Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024

Elicera Therapeutics AB (publ) Receives Notice of Allowance for European Patent Protecting the iTANK

New major risk - Financial position

Elicera Therapeutics AB (publ) Submits Clinical Trial Application to Evaluate Its CAR T-Cell Therapy in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Continues Phase I/IIa Study with Oncolytic Virus as Planned, Following Safety Review in Cohort 3

Elicera Therapeutics AB (publ) Announces Positive Clinical Effect in Cancer Trial

Elicera Therapeutics Reports Additional Signals of Clinical Activity in Patients Treated for Neuroendocrine Tumors in the Elc-100 Study At the Oncolytic Virotherapy Summit in Boston

Elicera Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Receives EUR 2.5 Million Funding to Fully Finance Clinical Phase I/II-Trial with its Car T-Cell Therapy, ELC-301

Elicera Therapeutics Successfully Concludes Preclinical Proof-Of-Concept Studies for Oncolytic Virus ELC-201 Confirming the Proposed Mode-Of-Action

High number of new and inexperienced directors

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Enters into Agreement with Baylor College of Medicine for Contract Manufacturing of Next Generation Oncolytic Virus, ELC-201

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter